Compare Abeona Therapeutics Inc (ABEO) vs Workday Inc (WDAY) Price & Performance

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Workday (WDAY) trades at $174.5, down 5.26% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, reaching $8.45B in 2025, with consistent earnings beats and a high gross margin of 75.77%. Recent news highlights product launches like Workday Adaptive Planning's FedRAMP authorization and an AI-native learning platform, reinforcing its enterprise software leadership.

Outlook remains positive with robust fundamentals and analyst support, though elevated valuation ratios like a P/E of 56.47 pose risks. Key opportunities include AI-driven growth in HR and finance software, while risks involve competitive pressures and market volatility. The consensus price target of $153.33 suggests caution near current levels, but long-term growth prospects are solid.